Evaluation of the 1-Year Efficacy and Tolerability of Inclisiran in Coronary Artery Disease Patients

In this single-center cohort, inclisiran was associated with sustained LDL-C reductions and acceptable tolerability over 1 year.

Authors

Institutions

Publication Details

Journal
Circulation Reports
Published
2026-01-21
DOI
https://doi.org/10.1253/circrep.cr-25-0279
Primary Topic
Peroxisome Proliferator-Activated Receptors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of the 1-Year Efficacy and Tolerability of Inclisiran in Coronary Artery Disease Patients

Shigeyasu Tsuda, Akihiro Yoshida, Shinichiro Yamada
Circulation Reports
Peroxisome Proliferator-Activated Receptors
article

Evaluation of the 1-Year Efficacy and Tolerability of Inclisiran in Coronary Artery Disease Patients

Shigeyasu Tsuda, Akihiro Yoshida, Shinichiro Yamada
article en

Abstract

In this single-center cohort, inclisiran was associated with sustained LDL-C reductions and acceptable tolerability over 1 year.

Circulation ReportsVol. 8(3)
Tokyo-Kita Medical Center (JP)
Good health and well-being
Openalex Percentile: Top 80%
Peroxisome Proliferator-Activated Receptors
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Evaluation of the 1-Year Efficacy and Tolerability of Inclisiran in Coronary Artery Disease Patients — Shigeyasu Tsuda, Akihiro Yoshida, et al. · Circulation Reports (2026) | TGRS Research Map | TGRS